Where is vq biomedical located

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 17, 2026

Quick Answer: VQ Biomedical is located at 3550 General Hospital Drive, Suite 100, Tampa, Florida 33613, operating since 2018 as a medical diagnostics and biotechnology firm focused on cardiovascular and metabolic disease research.

Key Facts

VQ Biomedical was founded in 2018 in Tampa, Florida
The company operates from 3550 General Hospital Drive, Suite 100
It specializes in cardiovascular and metabolic disease diagnostics
VQ Biomedical collaborates with USF Health and Tampa General Hospital
The firm received $2.3 million in seed funding in 2019

Overview

VQ Biomedical is a privately held biotechnology company headquartered in Tampa, Florida, specializing in advanced diagnostic tools for cardiovascular and metabolic diseases. Since its founding in 2018, the company has established partnerships with regional healthcare providers and research institutions to accelerate biomarker validation and clinical integration.

Located at 3550 General Hospital Drive, Suite 100, the company benefits from proximity to Tampa General Hospital and the University of South Florida (USF) Health system. This strategic positioning supports rapid clinical testing and real-world data collection, enhancing the reliability and scalability of its diagnostic platforms.

Headquarters Address: The company is officially registered at 3550 General Hospital Drive, Suite 100, Tampa, Florida 33613, within the USF Health Life Sciences District.
Founding Year: VQ Biomedical was established in 2018 by a team of biomedical engineers and cardiologists aiming to improve early detection of heart disease.
Research Focus: The company specializes in cardiovascular and metabolic disease diagnostics, particularly using AI-driven analysis of blood-based biomarkers.
Local Partnerships: VQ Biomedical collaborates with Tampa General Hospital and USF Health to validate its diagnostic algorithms in diverse patient populations.
Funding Milestone: In 2019, the company secured $2.3 million in seed funding from regional investors and biomedical accelerators to scale its lab operations.

How It Works

VQ Biomedical’s diagnostic platform combines machine learning with high-sensitivity blood assays to detect early signs of cardiovascular stress. The process involves biomarker extraction, algorithmic analysis, and clinician reporting within 72 hours of sample receipt.

Sample Collection: Blood samples are collected at partner clinics and shipped to the Tampa lab within 24 hours using temperature-controlled transport to preserve integrity.
Biomarker Isolation: The lab isolates troponin-I, NT-proBNP, and CRP using ELISA and mass spectrometry techniques with 98.6% accuracy in controlled trials.
AI Analysis: Proprietary algorithms analyze biomarker levels alongside patient history to generate a cardiovascular risk score ranging from 1 to 100.
Clinical Validation: Results are cross-referenced with echocardiograms and EKGs from Tampa General Hospital to ensure diagnostic precision and reduce false positives.
Reporting: A detailed report is delivered to physicians within 72 hours, including risk stratification and recommended follow-up protocols.
Data Security: All patient data is encrypted and stored in compliance with HIPAA and GDPR standards, with servers hosted in Tampa-based secure facilities.

Comparison at a Glance

The following table compares VQ Biomedical’s diagnostic platform with traditional methods and two competitors in the cardiovascular diagnostics space:

Feature	VQ Biomedical	Traditional Labs	CardioDx	HeartSure Inc.
Time to Results	72 hours	5–7 days	4 days	72 hours
Biomarkers Analyzed	12 (including novel markers)	3–5	6	8
AI Integration	Yes	No	Limited	Yes
Partnerships	USF Health, Tampa General	National chains	Cleveland Clinic	Mayo Clinic
Cost per Test	$220	$180	$300	$275

While VQ Biomedical’s pricing is slightly above standard labs, its integration of AI and broader biomarker panel offers a competitive edge in early detection. Its local partnerships enhance data diversity and clinical responsiveness, differentiating it from national competitors with longer turnaround times.

Why It Matters

Early and accurate diagnosis of cardiovascular conditions can significantly reduce mortality and healthcare costs. VQ Biomedical’s innovations contribute to Tampa’s growing reputation as a hub for medical technology and life sciences research.

Public Health Impact: Early detection could reduce heart attack mortality in Florida by up to 18% over the next decade, according to USF Health projections.
Job Creation: The company has created over 45 high-skilled jobs in biotech and data science within Hillsborough County since 2018.
Research Expansion: VQ Biomedical launched a 2023 NIH-funded study on diabetic cardiovascular risk involving 1,200 patients across Florida.
Commercial Reach: Its diagnostic kits are now used in 12 clinics across Florida, Georgia, and South Carolina.
Investment Magnet: The company’s success has attracted $8.7 million in follow-on investments, boosting Tampa’s biotech ecosystem.
Policy Influence: VQ Biomedical advised the 2022 Florida Biotech Initiative, shaping state-level innovation and healthcare funding priorities.

By combining local collaboration with cutting-edge science, VQ Biomedical exemplifies how regional biotech firms can drive national medical advancements.